.

Escitalopram Oxalate Powder | Raw Antidepressants | MDD & GAD Treatment

» Pharmaceutical » Antidepressants » Escitalopram Oxalate Powder | Raw Antidepressants | MDD & GAD Treatment

  • Specifications

Buy Escitalopram Oxalate Powder Raw Antidepressants For MDD & GAD Treatment CAS 219861-08-2

 

What is Escitalopram?

Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults and children over 12 years of age with major depressive disorder (MDD) and generalized anxiety disorder (GAD). Escitalopram is the (S)-stereoisomer (Left-enantiomer) of the earlier Lundbeck drug citalopram, hence the name escitalopram. Whether escitalopram exhibits superior therapeutic properties to citalopram or merely represents an example of “evergreening” is controversial.

 

Escitalopram Oxalate Basic information

Product Name:Escitalopram oxalate
ynonyms:(S)-CITALOPRAM;1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran-carbonitrile oxalate;ESCITALOPRAM OXALATE;S-(+)-CITAPROLAM OXALATE;S-(+)-1-3-(dimethyl-amino)propyl-1-(p-fluorophenyl)-5-phthalancarbonitrileoxalate;ESCIFALOPRAMOXALATE;(1S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile Ethanedioate;Cipralex
CAS:219861-08-2
MF:C22H23FN2O5
mp :152-153°C
storage temp. :-20°C Freezer, Under Inert Atmosphere
Chemical Properties:White Solid
Usage:An inhibitor of serotonin (5-HT) uptake. Antidepressant
Usage:A labelled inhibitor of serotonin (5-HT) uptake. Antidepressant
Usage:antineoplastic

 

Escitalopram oxalate Certificate of Analysis

Product name Escitalopram oxalate
CAS No. 219861-08-2 Outer Packing 1kg/bag
Production date Feb 2nd 2018 Shelf life Feb 1st 2020
Standard adopted USP37
Item Requirements Test Results
Appearance White to slightly  yellow powder White powder
Identifications A:IR: Conforms to spectrum of Escitalopram Oxalate RS Conforms to spectrum of Escitalopram
 Oxalate RS
B:The retention time of  the major peak of sample 
solution corresponds to that of the standard solution, 
as obtained Assay
The retention time of  the major peak of 
sample solution corresponds to that of the 
standard solution, as obtained Assay
Water ≤1.0% 0.5%
Residue on ignition ≤0.10% 0.04%
Enantiomeric purity ≤3.0% 0.3%
Organic impurities 5-Dimethylaminobutyryl citalopram  : ≤0.20% Undetected 
Citalopram related compound A: ≤0.10% Undetected
Citalopram related compound B:≤0.10% Undetected
Citalopram related compound C:≤0.10% 0.05%
Citalopram related compound D:≤0.10% Undetected
Citalopram related compound E:≤0.10% 0.03%
Individual unspecific impurity: ≤0.10% RRT=1.09:0.07%; RRT=1.17:0.01%; 
RRT=1.22:0.02% 
Total impurities: ≤0.50% 0.18%
Residual solvents Acetone: ≤0.50% Undetected
Toluene : ≤0.089% Undetected
Ethanol: ≤0.5% 0.02%
Acetic acid ≤0.5% Undetected
Triethylamine: ≤0.10% Undetected
Isopropanol: ≤0.5% Undetected
Dichloromethane ≤0.06 Undetected
2-Methylterahydrofuran: ≤0.0002% Undetected
Benzene: ≤0.0002% Undetected
Heavy metals ≤0.002% complies
Assay 98.0~102.0%(Calculated on anhydrous basis) 100.3%
Conclusion The above material complies with USP37

Enquiry Form ( we will get back you as soon as possible )

Name:
*
Email:
*
Message:

Verification:
0 + 6 = ?

Maybe you like also